KLRC2 Human Recombinant produced in E. coli is a single polypeptide chain containing 162 amino acids (94-231) and having a molecular mass of 18.4 kDa.KLRC2 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
KLRC2 Human
目录号: GP23759纯度: >98%
Killer Cell Lectin-Like Receptor Subfamily C, Member 2 Human Recombinant
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 2μg | ¥840.00 | 现货 | 1 | |
| 10μg | ¥2,030.00 | 现货 | 1 | |
| 1mg | ¥72,800.00 | 现货 | 1 |
电话: 400-920-5774Email: sales@glpbio.cn
文献被引
本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
Nature641, 529–536 (2025)
Nature628, 630–638 (2024)
Nature632, 686–694 (2024)
Nature618, 1017–1023 (2023)
Nature610, 366–372 (2022)
Cell187(9):2288-2304 (2024)
Cell183(7):1867-1883 (2020)
Science388(6745) (2025)
Science387(6739) (2025)
Science387(6734) (2025)
Cell Research35, 97–116 (2025)
Cell Research34, 683–706 (2024)
Cell Research33, 273–287 (2023)
Cell Research33, 546–561 (2023)
Cell Research33, 904–922 (2023)
Cell Research31, 1291–1307 (2021)
产品描述 Description
产品文档 Product Documents
Purity:>98%
Product Data
Purity
Greater than 85% as determined by SDS-PAGE.
Source
E.coli.
Physical Appearance
Sterile Filtered colorless solution.
Shipping Condition
Shipped with Ice Packs.
Synonyms
Killer cell lectin-like receptor subfamily C member 2; NKG2-C type II integral membrane protein; NKG2-C-activating NK receptor; CD159 antigen-like family member C; NK cell receptor C; NKG2C; CD159c.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMIPFLEQ NNFSPNTRTQ KARHCGHCPE EWITYSNSCY YIGKERRTWE ESLLACTSKN SSLLSIDNEE EMKFLASILP SSWIGVFRNS SHHPWVTING LAFKHKIKDS DNAELNCAVL QVNRLKSAQC GSSMIYHCKH KL
Stability
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.
Formulation
The KLRC2 solution (0.5mg/1ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.4M urea and 10% glycerol.
